BridgeBio Pharma, Inc. (BBIO)

BridgeBio to Present New Acoramidis Data from Open-Label Extension Analyses in ATTR-CM at ESC Congress 2026

BridgeBio Stock Has Soared 29% in Just 3 Months. Here's Why Wall Street Thinks It Could Go Even Higher.

BridgeBio Pharma Announces Pricing of Oversubscribed Secondary Offering that Diversifies its Institutional Shareholder Base

BridgeBio Pharma Announces Launch of Secondary Offering of Common Stock on Behalf of an Existing Shareholder

BridgeBio Pharma Q2 Earnings Call Highlights

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Q2 Earnings Miss, Revenues Beat as Attruby Sales Surge

BridgeBio: Attruby Delivers In Q2, Expect Three New Launches In 12 Months

4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year

BridgeBio Pharma, Inc. (BBIO) Q2 2026 Earnings Call Transcript

BridgeBio Pharma (BBIO) Reports Q2 Loss, Tops Revenue Estimates

BridgeBio Pharma Q2 Earnings Call Highlights

California State Teachers Retirement System Boosts Stock Position in BridgeBio Pharma, Inc. $BBIO

BridgeBio to Report Second Quarter 2026 Financial Results and Commercial Updates on August 10, 2026 at 4:30 pm ET

1 Top Wall Street Analyst Thinks This Stock Could Soar 95% Over the Next 12 Months. Here's Why I Agree.

BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: Should You Buy?

Affinity Asset Advisors LLC Has $11.14 Million Stock Holdings in BridgeBio Pharma, Inc. $BBIO

California Public Employees Retirement System Grows Stock Holdings in BridgeBio Pharma, Inc. $BBIO

FDA Accepts BridgeBio's Filing for Rare Genetic Disease Drug

BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1